JP2001514000A5 - - Google Patents

Download PDF

Info

Publication number
JP2001514000A5
JP2001514000A5 JP2000507804A JP2000507804A JP2001514000A5 JP 2001514000 A5 JP2001514000 A5 JP 2001514000A5 JP 2000507804 A JP2000507804 A JP 2000507804A JP 2000507804 A JP2000507804 A JP 2000507804A JP 2001514000 A5 JP2001514000 A5 JP 2001514000A5
Authority
JP
Japan
Prior art keywords
nucleic acid
domain
cell
eliciting
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000507804A
Other languages
English (en)
Japanese (ja)
Other versions
JP4255209B2 (ja
JP2001514000A (ja
Filing date
Publication date
Priority claimed from EP97114614A external-priority patent/EP0902086A1/en
Application filed filed Critical
Publication of JP2001514000A publication Critical patent/JP2001514000A/ja
Publication of JP2001514000A5 publication Critical patent/JP2001514000A5/ja
Application granted granted Critical
Publication of JP4255209B2 publication Critical patent/JP4255209B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000507804A 1997-08-22 1998-08-12 結核ワクチン Expired - Lifetime JP4255209B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97114614A EP0902086A1 (en) 1997-08-22 1997-08-22 Tuberculosis vaccine
EP97114614.7 1997-08-22
PCT/EP1998/005109 WO1999010496A1 (en) 1997-08-22 1998-08-12 Tuberculosis vaccine

Publications (3)

Publication Number Publication Date
JP2001514000A JP2001514000A (ja) 2001-09-11
JP2001514000A5 true JP2001514000A5 (https=) 2006-01-05
JP4255209B2 JP4255209B2 (ja) 2009-04-15

Family

ID=8227261

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000507804A Expired - Lifetime JP4255209B2 (ja) 1997-08-22 1998-08-12 結核ワクチン

Country Status (13)

Country Link
US (1) US6673353B1 (https=)
EP (2) EP0902086A1 (https=)
JP (1) JP4255209B2 (https=)
AT (1) ATE347599T1 (https=)
AU (1) AU9435098A (https=)
CA (1) CA2301879C (https=)
CY (1) CY1106350T1 (https=)
DE (1) DE69836588T2 (https=)
DK (1) DK1007686T3 (https=)
ES (1) ES2274580T3 (https=)
PT (1) PT1007686E (https=)
SI (1) SI1007686T1 (https=)
WO (1) WO1999010496A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072329A1 (en) 2000-03-29 2001-10-04 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
US7662396B2 (en) 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
ID29858A (id) 1998-11-04 2001-10-18 Isis Innovation Uji diagnostik tuberkulosis
GB0006693D0 (en) * 2000-03-20 2000-05-10 Glaxo Group Ltd Vaccine
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
KR101192652B1 (ko) * 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
PT1618128E (pt) * 2003-04-23 2010-10-13 Max Planck Gesellschaft Vacina de tuberculose com eficácia melhorada
EP1649869A1 (en) 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
CN101198358B (zh) * 2004-12-01 2013-06-26 Aeras全球Tb疫苗基金会 具有增强的逃出内体能力的重组bcg菌株
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
DK2977456T3 (en) 2006-08-15 2018-01-22 Univ Pennsylvania Compositions comprising HMW-MAA and fragments thereof for the treatment of cancer
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US20110129499A1 (en) 2008-05-19 2011-06-02 Paulo Maciag Dual delivery system for heterologous antigens
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
PT2403935T (pt) 2009-03-04 2017-09-22 Univ Pennsylvania Composições compreendendo fatores angiogénicos e metedos para a sua utilização
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
HUE039038T2 (hu) * 2010-09-20 2018-12-28 Vakzine Projekt Man Gmbh Rekombináns mycobakterium, mint emberekben alkalmazható vakcina
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
JP6006909B2 (ja) * 2010-12-21 2016-10-12 マックス−プランク−ゲゼルシャフト ツール フェルデルンク デル ヴィッセンシャフテン エー.ファウ. ワクチンとしての組み換えマイコバクテリウム
SI2656070T1 (sl) 2010-12-21 2016-05-31 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Ugotavljanje učinkovitosti živega rekombinantnega antimikobakterijskega cepljenja
AU2012229218B2 (en) 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
BR102012003790A2 (pt) 2012-02-17 2014-04-22 Fundacao Butantan Cepa de mycobacterium recombinante, composição imunogênica e uso
CN104411327A (zh) 2012-03-12 2015-03-11 阿德瓦希斯公司 李斯特菌疫苗治疗以后的抑制细胞功能抑制
EP2834356A4 (en) * 2012-04-02 2015-09-02 Univ Arizona RECOMBINANT BACTERIUM FOR INDUCING A CELLULAR IMMUNE RESPONSE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504005A (en) * 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine

Similar Documents

Publication Publication Date Title
JP2001514000A5 (https=)
JP3485916B2 (ja) 組み換えマイコバクテリアの発現ベヒクルおよびその使用
EP1303299B1 (en) Use of prokaryotic pest-like peptides for enhancing immunogenicity of antigens
Stover et al. New use of BCG for recombinant vaccines
US5591632A (en) Recombinant BCG
US6855320B2 (en) Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
CA2523084A1 (en) Tuberculosis vaccine with improved efficacy
Crocquet-Valdes et al. Immunization with a portion of rickettsial outer membrane protein A stimulates protective immunity against spotted fever rickettsiosis
EP1537214B1 (en) Regulated bacterial lysis for gene vaccine vector delivery and antigen release
AU2010238943A1 (en) A tuberculosis TB vaccine to prevent reactivation
JP2007332149A (ja) マイコバクテリア感染症に対するワクチン
Zhu et al. Vaccination with recombinant vaccinia viruses protects mice against Mycobacterium tuberculosis infection
TWI221847B (en) Clostridium perfringens vaccine
JP2003510018A5 (https=)
Armengol et al. The injection of plasmid DNA in mouse muscle results in lifelong persistence of DNA, gene expression, and humoral response
EP1348036A2 (en) Protection against mycobacterial infections
Deng et al. Improved Immunogenicity of Recombinant Mycobacterium bovis Bacillus Calmette‐Guérin Strains Expressing Fusion Protein Ag85A‐ESAT‐6 of Mycobacterium tuberculosis
Fuerst et al. Development and analysis of recombinant BCG vector systems
Faludi et al. Recombinant Mycobacterium smegmatis vaccine candidates
WO2006053485A1 (fr) Vaccin genique contre le bacille mycobacterium tuberculosis obtenu a partir d’un gene chimere et procede de preparation dudit vaccin
US8299232B2 (en) Constructing a DNA chimera for vaccine development against leishmaniasis and tuberculosis
Martin et al. Comparative protective effects of recombinant DNA and Mycobacterium bovis bacille Calmette–Guérin vaccines against M. avium infection
Nosareva et al. Construction of an encapsulated ESAT-6-based anti-TB DNA vaccine and evaluation of its immunogenic properties.
Norazmi et al. The use of assembly polymerase chain reaction for cloning of a malarial epitope into Mycobacterium smegmatis–importance of overcoming codon bias
JP2002114708A (ja) Dnaワチンに対するアジュバント剤